Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

• Status: Recruiting
• Trial end date: 2024-09-01

Summary

Randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type Acute Myeloid Leukemia

• Phase: Phase 2

Details

• Lead Sponsor: PETHEMA Foundation
• Collaborators: Daiichi Sankyo, Inc.; Dynamic Science S.L.
• Treatments: Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Idarubicin